Bleeding diathesis: Difference between revisions
Jump to navigation
Jump to search
| Line 14: | Line 14: | ||
! rowspan="2" |Sub-category | ! rowspan="2" |Sub-category | ||
! rowspan="2" |Diseases | ! rowspan="2" |Diseases | ||
! rowspan="2" |History | ! rowspan="2" |History | ||
! colspan="5" |Clinical manifestation | ! colspan="5" |Clinical manifestation | ||
| Line 33: | Line 32: | ||
| rowspan="7" |'''[[Thrombocytopenia]]''' | | rowspan="7" |'''[[Thrombocytopenia]]''' | ||
|[[Infection]]-Induced Thrombocytopenia<span name="harr_c115s002s001s002p001"></span><span name="9100754"></span> | |[[Infection]]-Induced Thrombocytopenia<span name="harr_c115s002s001s002p001"></span><span name="9100754"></span> | ||
| | | | ||
| | | | ||
| Line 47: | Line 45: | ||
|- | |- | ||
|[[Medication|Medications]]-Induced Thrombocy<span name="harr_c115s002s001s003p001"></span><span name="9100757"></span>topenia | |[[Medication|Medications]]-Induced Thrombocy<span name="harr_c115s002s001s003p001"></span><span name="9100757"></span>topenia | ||
| | | | ||
| | | | ||
| Line 61: | Line 58: | ||
|- | |- | ||
|[[Heparin]]-Induced Thrombocytopenia<span name="harr_c115s002s001s004p001"></span><span name="9100761"></span> | |[[Heparin]]-Induced Thrombocytopenia<span name="harr_c115s002s001s004p001"></span><span name="9100761"></span> | ||
| | | | ||
| | | | ||
| Line 75: | Line 71: | ||
|- | |- | ||
|[[Idiopathic thrombocytopenic purpura|Immune Thrombocytopenic Purpura]] ([[Idiopathic thrombocytopenic purpura|ITP]])<span name="harr_c115s002s001s005p001"></span><span name="9100771"></span> | |[[Idiopathic thrombocytopenic purpura|Immune Thrombocytopenic Purpura]] ([[Idiopathic thrombocytopenic purpura|ITP]])<span name="harr_c115s002s001s005p001"></span><span name="9100771"></span> | ||
| | | | ||
| | | | ||
| Line 89: | Line 84: | ||
|- | |- | ||
|Inherited Thrombocytopenia<span name="harr_c115s002s001s006p001"></span><span name="9100783"></span> | |Inherited Thrombocytopenia<span name="harr_c115s002s001s006p001"></span><span name="9100783"></span> | ||
| | | | ||
| | | | ||
| Line 103: | Line 97: | ||
|- | |- | ||
|[[Thrombotic thrombocytopenic purpura|Thrombotic Thrombocytopenic Purpura]] ([[Thrombotic thrombocytopenic purpura|TTP]])<span name="harr_c115s002s002s001p001"></span><span name="9100787"></span> | |[[Thrombotic thrombocytopenic purpura|Thrombotic Thrombocytopenic Purpura]] ([[Thrombotic thrombocytopenic purpura|TTP]])<span name="harr_c115s002s002s001p001"></span><span name="9100787"></span> | ||
| | | | ||
| | | | ||
| Line 117: | Line 110: | ||
|- | |- | ||
|[[Hemolytic-uremic syndrome|Hemolytic Uremic Syndrome]]<span name="harr_c115s002s002s002p001"></span><span name="9100796"></span> | |[[Hemolytic-uremic syndrome|Hemolytic Uremic Syndrome]]<span name="harr_c115s002s002s002p001"></span><span name="9100796"></span> | ||
| | | | ||
| | | | ||
| Line 132: | Line 124: | ||
|Thromobcytosis<span name="harr_c115s002s003p001"></span><span name="9100800"></span> | |Thromobcytosis<span name="harr_c115s002s003p001"></span><span name="9100800"></span> | ||
|Thrombocytosis in response to acute or chronic inflammation has not been associated with an increased thrombotic risk. In fact, patients with markedly elevated platelet counts (>1.5 million), usually seen in the setting of a myeloproliferative disorder, have an increased risk of bleeding. This appears to be due, at least in part, to acquired von Willebrand disease (VWD) due to platelet-VWF adhesion and removal. | |Thrombocytosis in response to acute or chronic inflammation has not been associated with an increased thrombotic risk. In fact, patients with markedly elevated platelet counts (>1.5 million), usually seen in the setting of a myeloproliferative disorder, have an increased risk of bleeding. This appears to be due, at least in part, to acquired von Willebrand disease (VWD) due to platelet-VWF adhesion and removal. | ||
| | | | ||
| | | | ||
| Line 147: | Line 138: | ||
| rowspan="7" |Qualitative Disorders of [[Platelet]] Function<span name="harr_c115s002s004s001p001"></span><span name="9100803"></span> | | rowspan="7" |Qualitative Disorders of [[Platelet]] Function<span name="harr_c115s002s004s001p001"></span><span name="9100803"></span> | ||
|Inherited Disorders of [[Platelet]] Function<span name="harr_c115s002s004s001p001"></span><span name="9100803"></span> | |Inherited Disorders of [[Platelet]] Function<span name="harr_c115s002s004s001p001"></span><span name="9100803"></span> | ||
| | | | ||
| | | | ||
| Line 161: | Line 151: | ||
|- | |- | ||
|Acquired Disorders of [[Platelet]] Function<span name="harr_c115s002s004s002p001"></span><span name="9100808"></span> | |Acquired Disorders of [[Platelet]] Function<span name="harr_c115s002s004s002p001"></span><span name="9100808"></span> | ||
| | | | ||
| | | | ||
| Line 175: | Line 164: | ||
|- | |- | ||
| rowspan="5" |[[Von Willebrand disease|Von Willebrand Disease]]<span name="harr_c115s002s005p001"></span><span name="9100810"></span> | | rowspan="5" |[[Von Willebrand disease|Von Willebrand Disease]]<span name="harr_c115s002s005p001"></span><span name="9100810"></span> | ||
| | | | ||
| | | | ||
| Line 188: | Line 176: | ||
| | | | ||
|- | |- | ||
| | | | ||
| | | | ||
| Line 201: | Line 188: | ||
| | | | ||
|- | |- | ||
| | | | ||
| | | | ||
| Line 214: | Line 200: | ||
| | | | ||
|- | |- | ||
| | | | ||
| | | | ||
| Line 227: | Line 212: | ||
| | | | ||
|- | |- | ||
| | | | ||
| | | | ||
| Line 241: | Line 225: | ||
|- | |- | ||
| rowspan="2" |Vessel wall disorders | | rowspan="2" |Vessel wall disorders | ||
|[[Metabolism|Metabolic]] and [[Inflammation|Inflammatory]] Disorders | | colspan="2" |[[Metabolism|Metabolic]] and [[Inflammation|Inflammatory]] Disorders | ||
| | | | ||
| | | | ||
| Line 256: | Line 238: | ||
| | | | ||
|- | |- | ||
|Inherited Disorders of the [[Vessel wall|Vessel Wall]] | | colspan="2" |Inherited Disorders of the [[Vessel wall|Vessel Wall]] | ||
| | | | ||
| | | | ||
| Line 271: | Line 251: | ||
| | | | ||
|- | |- | ||
| rowspan=" | | rowspan="15" |Coagulation disorders | ||
|[[Fibrinogen]] deficiency | | colspan="2" |[[Fibrinogen]] deficiency | ||
| | | | ||
| | | | ||
| Line 287: | Line 265: | ||
| | | | ||
|- | |- | ||
|[[Prothrombin deficiency]] | | colspan="2" |[[Prothrombin deficiency]] | ||
| | | | ||
| | | | ||
| Line 302: | Line 278: | ||
| | | | ||
|- | |- | ||
| rowspan="1" |[[Factor V deficiency]] | | colspan="2" rowspan="1" |[[Factor V deficiency]] | ||
| | | | ||
| | | | ||
| Line 317: | Line 291: | ||
| | | | ||
|- | |- | ||
| rowspan="1" |[[Factor VII deficiency]] | | colspan="2" rowspan="1" |[[Factor VII deficiency]] | ||
| | | | ||
| | | | ||
| Line 332: | Line 304: | ||
| | | | ||
|- | |- | ||
| rowspan="1" |[[Factor VIII deficiency]] | | colspan="2" rowspan="1" |[[Factor VIII deficiency]] | ||
| | | | ||
| | | | ||
| Line 347: | Line 317: | ||
| | | | ||
|- | |- | ||
| rowspan="1" |Factor IX deficiency | | colspan="2" rowspan="1" |Factor IX deficiency | ||
| | | | ||
| | | | ||
| Line 362: | Line 330: | ||
| | | | ||
|- | |- | ||
| rowspan="1" |[[Factor X deficiency]] | | colspan="2" rowspan="1" |[[Factor X deficiency]] | ||
| | | | ||
| | | | ||
| Line 377: | Line 343: | ||
| | | | ||
|- | |- | ||
| rowspan="1" |[[Factor XI|Factor XI deficiency]] | | colspan="2" rowspan="1" |[[Factor XI|Factor XI deficiency]] | ||
| | | | ||
| | | | ||
| Line 392: | Line 356: | ||
| | | | ||
|- | |- | ||
| rowspan="1" |[[Factor XII|Factor XII deficiency]] | | colspan="2" rowspan="1" |[[Factor XII|Factor XII deficiency]] | ||
| | | | ||
| | | | ||
| Line 407: | Line 369: | ||
| | | | ||
|- | |- | ||
|HK deficiency | | colspan="2" |HK deficiency | ||
| | | | ||
| | | | ||
| Line 422: | Line 382: | ||
| | | | ||
|- | |- | ||
| rowspan="1" |[[Prekallikrein]] deficiency | | colspan="2" rowspan="1" |[[Prekallikrein]] deficiency | ||
| | | | ||
| | | | ||
| Line 437: | Line 395: | ||
| | | | ||
|- | |- | ||
| rowspan="1" |[[Factor XIII deficiency]] | | colspan="2" rowspan="1" |[[Factor XIII deficiency]] | ||
| | | | ||
| | | | ||
| Line 454: | Line 410: | ||
| rowspan="3" |[[Hemophilia]] | | rowspan="3" |[[Hemophilia]] | ||
|Type A deficiency | |Type A deficiency | ||
| | | | ||
| | | | ||
| Line 469: | Line 423: | ||
|- | |- | ||
|Type B deficiency | |Type B deficiency | ||
| | | | ||
| | | | ||
| Line 484: | Line 436: | ||
|- | |- | ||
|Type C deficiency | |Type C deficiency | ||
| | | | ||
| | | | ||
| Line 499: | Line 449: | ||
|- | |- | ||
| rowspan="4" |Rare diseases | | rowspan="4" |Rare diseases | ||
|[[Disseminated intravascular coagulation|Disseminated Intravascular Coagulation]] | | colspan="2" |[[Disseminated intravascular coagulation|Disseminated Intravascular Coagulation]] | ||
| | | | ||
| | | | ||
| Line 514: | Line 462: | ||
| | | | ||
|- | |- | ||
|[[Vitamin K Deficiency]] | | colspan="2" |[[Vitamin K Deficiency]] | ||
| | | | ||
| | | | ||
| Line 529: | Line 475: | ||
| | | | ||
|- | |- | ||
|Coagulation Disorders Associated with [[Hepatic failure|Liver Failure]] | | colspan="2" |Coagulation Disorders Associated with [[Hepatic failure|Liver Failure]] | ||
| | | | ||
| | | | ||
| Line 544: | Line 488: | ||
| | | | ||
|- | |- | ||
|Acquired Inhibitors of Coagulation Factors | | colspan="2" |Acquired Inhibitors of Coagulation Factors | ||
| | | | ||
| | | | ||
Revision as of 13:12, 24 August 2018
|
Bleeding diathesis main page |
|
|---|
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Mehrian Jafarizade, M.D [2]
Overview
Classification
Differential Diagnosis
| Category | Sub-category | Diseases | History | Clinical manifestation | Laboratory testing | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Petechiae | Ecchymoses | Menorrhagia | Hematomas | Hemarthrosis | platelet count | Bleeding time (BT) | Prothrombin time (PT) | Platelet count activated partial thromboplastin time (aPTT) | Thrombin time (TT) | ||||
| Platelet disorders | Thrombocytopenia | Infection-Induced Thrombocytopenia | |||||||||||
| Medications-Induced Thrombocytopenia | |||||||||||||
| Heparin-Induced Thrombocytopenia | |||||||||||||
| Immune Thrombocytopenic Purpura (ITP) | |||||||||||||
| Inherited Thrombocytopenia | |||||||||||||
| Thrombotic Thrombocytopenic Purpura (TTP) | |||||||||||||
| Hemolytic Uremic Syndrome | |||||||||||||
| Thromobcytosis | Thrombocytosis in response to acute or chronic inflammation has not been associated with an increased thrombotic risk. In fact, patients with markedly elevated platelet counts (>1.5 million), usually seen in the setting of a myeloproliferative disorder, have an increased risk of bleeding. This appears to be due, at least in part, to acquired von Willebrand disease (VWD) due to platelet-VWF adhesion and removal. | ||||||||||||
| Qualitative Disorders of Platelet Function | Inherited Disorders of Platelet Function | ||||||||||||
| Acquired Disorders of Platelet Function | |||||||||||||
| Von Willebrand Disease | |||||||||||||
| Vessel wall disorders | Metabolic and Inflammatory Disorders | ||||||||||||
| Inherited Disorders of the Vessel Wall | |||||||||||||
| Coagulation disorders | Fibrinogen deficiency | ||||||||||||
| Prothrombin deficiency | |||||||||||||
| Factor V deficiency | |||||||||||||
| Factor VII deficiency | |||||||||||||
| Factor VIII deficiency | |||||||||||||
| Factor IX deficiency | |||||||||||||
| Factor X deficiency | |||||||||||||
| Factor XI deficiency | |||||||||||||
| Factor XII deficiency | |||||||||||||
| HK deficiency | |||||||||||||
| Prekallikrein deficiency | |||||||||||||
| Factor XIII deficiency | |||||||||||||
| Hemophilia | Type A deficiency | ||||||||||||
| Type B deficiency | |||||||||||||
| Type C deficiency | |||||||||||||
| Rare diseases | Disseminated Intravascular Coagulation | ||||||||||||
| Vitamin K Deficiency | |||||||||||||
| Coagulation Disorders Associated with Liver Failure | |||||||||||||
| Acquired Inhibitors of Coagulation Factors | |||||||||||||